Chemotherapy and cognitive complaints in women with breast cancer

Psycho-Oncology

Volumn 22, Issue 8, 2013, Pages 1783-1789

  Pullens, Marleen J J ^a   De Vries, Jolanda ^a,b   Van Warmerdam, Laurence J C ^c   Van De Wal, Marieke A ^d   Roukema, Jan A ^a,b  

^a TILBURG UNIVERSITY   (Netherlands)

^b Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^c CATHARINA HOSPITAL   (Netherlands)

^d MÁXIMA MEDICAL CENTER   (Netherlands)

Author keywords

breast cancer; cancer; chemotherapy; cognitive complaints; oncology; subjective cognitive functioning

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; BREAST CANCER; BREAST DISEASE; CANCER CHEMOTHERAPY; DEPRESSION; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PATIENT SATISFACTION; QUESTIONNAIRE; STRESS;

BREAST CANCER; CANCER; CHEMOTHERAPY; COGNITIVE COMPLAINTS; ONCOLOGY; SUBJECTIVE COGNITIVE FUNCTIONING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANXIETY; ANXIETY DISORDERS; BREAST DISEASES; BREAST NEOPLASMS; COGNITION; COGNITION DISORDERS; DEPRESSION; FATIGUE; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NETHERLANDS; PERSONAL SATISFACTION; PREVALENCE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; REGRESSION ANALYSIS;

EID: 84880660946     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.3214     Document Type: Article

References (37)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P,. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18 (3): 581-592.
2. Pullens MJJ, De Vries J, Roukema JA,. Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psycho-Oncology 2010; 19 (11): 1127-1138.
3. Hermelink K, Kuchenhoff H, Untch M, et al. Two different sides of 'chemobrain': determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psycho-Oncology 2010; 19 (12): 1321-1328.
4. Quesnel C, Savard J, Ivers H,. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 2009; 116 (1): 113-123.
5. Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006; 94 (6): 828-834.
6. Debess J, Riis JO, Engebjerg MC, Ewertz M,. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Res Treat 2010; 121 (1): 91-100.
7. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF,. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85 (3): 640-650.
8. Shilling V, Jenkins V,. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 2007; 11 (1): 6-15.
9. Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB,. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer 2005; 104 (11): 2499-2507.
10. Servaes P, Van der Werf S, Prins J, Verhagen S, Bleijenberg G,. Fatigue in disease-free cancer patients compared with fatigue in patients with chronic fatigue syndrome. Support Care Cancer 2001; 9 (1): 11-17.
11. Reid LM, Maclullich AM,. Subjective memory complaints and cognitive impairment in older people. Dement Geriatr Cogn Disord 2006; 22 (5-6): 471-485.
12. Debess J, Riis JO, Pedersen L, Ewertz M,. Cognitive function and quality of life after surgery for early breast cancer in North Jutland, Denmark. Acta Oncol 2009; 48 (4): 532-540.
13. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR,. The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol 1982; 21 (Pt 1): 1-16.
14. Murris M,. De 'Cognitive Failure Questionnaire' (CFQ). Gedragstherapie 1995; 28: 123-128.
15. De Vries J, Van Heck GL,. The Dutch Version of the WHOQOL-100. Tilburg University: Tilburg, 1995.
16. O'Carroll RE, Smith K, Couston M, Cossar JA, Hayes PC,. A comparison of the WHOQOL-100 and the WHOQOL-BREF in detecting change in quality of life following liver transplantation. Qual Life Res 2000; 9 (1): 121-124.
17. De Vries J, Van Heck GL,. The World Health Organization Quality of Life assessment instrument (WHOQOL-100): validation study with the Dutch version. Eur J Psychol Assess 1997; 13: 164-178.
18. Radloff LS,. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psych Meas 1977; 1 (3): 385-401.
19. Bouma J, Ranchor AV, Sanderman R,. et al. CES-D, Groningen. Noordelijk centrum voor gezondheidsvraagstukken: Rijksuniversiteit Groningen, Groningen, 1995.
20. Hann D, Winter K, Jacobsen P,. Measurement of depressive symptoms in cancer patients: evaluation of the Center for Epidemiological Studies Depression Scale (CES-D). J Psychosom Res 1999; 46 (5): 437-443.
21. Michielsen HJ, De Vries J, Van Heck GL,. Psychometric qualities of a brief self-rated fatigue measure: The Fatigue Assessment Scale. J Psychosom Res 2003; 54 (4): 345-352.
22. Michielsen HJ, Van der Steeg AF, Roukema JA, De Vries J,. Personality and fatigue in patients with benign or malignant breast disease. Support Care Cancer 2007; 15 (9): 1067-1073.
23. Spielberger CD, Gorsuch RL, Lushene RE,. The State-Trait Anxiety Inventory Manual. Consulting Psychologists Press: Palo Alto, CA, 1970.
24. Van der Ploeg HM, Defares PB, Spielberger CD,. ZBV. A Dutch-language Adaptation of the Spielberger State-Trait Anxiety Inventory. Swets&Zeitlinger: Lisse, The Netherlands, 1980.
25. Marteau TM, Bekker H,. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol 1992; 31 (Pt 3): 301-306.
26. Van der Bij AK, de Weerd S, Cikot RJ, Steegers EA, Braspenning JC,. Validation of the Dutch short form of the state scale of the Spielberger State-Trait Anxiety Inventory: considerations for usage in screening outcomes. Community Genet 2003; 6 (2): 84-87.
27. Bogaarts MP, Den Oudsten BL, Roukema JA, Van Riel JM, Beerepoot LV, De Vries J,. Development of the Psychosocial Distress Questionnaire-Breast Cancer (PDQ-BC): a Breast Cancer specefic screening instrument of psychosocial problems. Support Care Cancer 2011; 19: 1485-1493.
28. Cohen S, Kamarck T, Mermelstein R,. A global measure of perceived stress. J Health Soc Behav 1983; 24 (4): 385-396.
29. Twisk JWR,. Inleiding in te Toegepaste Biostatistiek (Introduction in Applied Biostatistics). Elsevier Gezondheidszorg: Maarssen, The Nederlands, 2007.
30. Sarason BR, Sarason IG, Pierce GR,. Social Support an Interactional View. J. Wiley & Sons: New York, USA, 1990.
31. Schagen S, Das E, Vermeulen I,. Information about chemotherapy-associated cognitive problems contributes to cognitive problems in cancer patients. Psycho-Oncology 2011. DOI: 10.1002/pon.2011
32. Schilder CM, Seynaeve C, Linn SC,. Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study. Psycho-Oncology 2011. doi: 10.1002/pon.1928
33. Cimprich B, So H, Ronis DL, Trask C,. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psycho-Oncology 2005; 14 (1): 70-78.
34. Breckenridge LM, Bruns GL, Todd BL, Feuerstein M,. Cognitive limitations associated with tamoxifen and aromatase inhibitors in employed breast cancer survivors. Psycho-Oncology 2010. doi: 10.1002/pon.1860
35. Schilder CM, Eggens PC, Seynaeve C, et al. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 2009; 48 (1): 76-85.
36. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S,. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho-Oncology 2004; 13 (1): 61-66.
37. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA,. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004; 26 (7): 955-969.